| Scenario | Answer | |----------|--------| | | Used for locally advanced (e.g., H&N, cervical, lung). Most effective but most toxic. | | Neoadjuvant (chemo first) | For bulky disease where RT fields would be too large (e.g., anal cancer, rectal cancer – though often both). | | Adjuvant (RT after chemo) | For high-risk features after surgery (e.g., breast, endometrial). |
| Highly sensitive | Moderately sensitive | Resistant | |----------------|----------------------|-----------| | Lymphoma, Seminoma, SCLC | Squamous cell (H&N, cervical), Breast, NSCLC | Melanoma, Renal cell, Sarcoma (high dose needed) | Resistance often requires SBRT (ablative dose) or combination with systemic therapy. 3. The "Answer Formula" for Clinical Scenarios When asked an open-ended question (e.g., "How would you treat this 68M with T2N1M0 NSCLC who is medically inoperable?" ): radoncquestions
❌ – a frail patient gets palliative, not definitive, regardless of stage. | Scenario | Answer | |----------|--------| | |
❌ – always ask, always document cumulative dose. | | Adjuvant (RT after chemo) | For